Search Results - "Forastiere, A."

Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment by Marur, Shanthi, MD, Forastiere, Arlene A., MD

“…Abstract Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. The risk factors for development of cancers of the oral…”
Get full text

HPV-associated head and neck cancer: a virus-related cancer epidemic by Marur, Shanthi, Dr, D'Souza, Gypsyamber, PhD, Westra, William H, Prof, Forastiere, Arlene A, Prof

“…Summary A rise in incidence of oropharyngeal squamous cell cancer—specifically of the lingual and palatine tonsils—in white men younger than age 50 years who…”
Get full text

Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment by Marur, Shanthi, MD, Forastiere, Arlene A., MD

“…Head and neck cancers account for less than 5% of all cancers and for less than 3% of all cancer deaths in the United States. The populations at risk for head…”
Get full text

Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes by Forastiere, Arlene A, Weber, Randal S, Trotti, Andy

“…To provide a review of the clinical data, controversies, and limitations that underpin current recommendations for approaches to larynx preservation for…”
Get full text

Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer by FORASTIERE, ArleneA, QIANGZHANG, THORSTAD, Wade, WAGNER, Henry, ENSLEY, John F, COOPER, Jay S, WEBER, Randal S, MAOR, Moshe H, GOEPFERT, Helmuth, PAJAK, Thomas F, MORRISON, William, GLISSON, Bonnie, TROTTI, Andy, RIDGE, John A

“…To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation…”
Get full text

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update by Forastiere, Arlene A, Ismaila, Nofisat, Lewin, Jan S, Nathan, Cherie Ann, Adelstein, David J, Eisbruch, Avraham, Fass, Gail, Fisher, Susan G, Laurie, Scott A, Le, Quynh-Thu, O'Malley, Bernard, Mendenhall, William M, Patel, Snehal, Pfister, David G, Provenzano, Anthony F, Weber, Randy, Weinstein, Gregory S, Wolf, Gregory T

“…Purpose To update the guideline recommendations on the use of larynx-preservation strategies in the treatment of laryngeal cancer. Methods An Expert Panel…”
Get full text

Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck by Cooper, Jay S., MD, Zhang, Qiang, PhD, Pajak, Thomas F., PhD, Forastiere, Arlene A., MD, Jacobs, John, MD, Saxman, Scott B., MD, Kish, Julie A., MD, Kim, Harold E., MD, Cmelak, Anthony J., MD, Rotman, Marvin, MD, Lustig, Robert, MD, Ensley, John F., MD, Thorstad, Wade, MD, Schultz, Christopher J., MD, Yom, Sue S., MD, Ang, K. Kian, MD, PhD

“…Purpose Previous analysis of this Intergroup trial demonstrated that with a median follow-up among surviving patients of 45.9 months, the concurrent…”
Get full text

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study by BURTNESS, Barbara, GOLDWASSER, Meredith A, FLOOD, William, MATTAR, Bassam, FORASTIERE, Arlene A

“…Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months. These cancers are…”
Get full text

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial by ARGIRIS, Athanassios, GHEBREMICHAEL, Musie, GILBERT, Jill, LEE, Ju-Whei, SACHIDANANDAM, Kamakshi, KOLESAR, Jill M, BURTNESS, Barbara, FORASTIERE, Arlene A

“…We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic…”
Get full text

Chemoradiation in the Management of Esophageal Cancer by Kleinberg, Lawrence, Forastiere, Arlene A

“…The combination of chemotherapy, fluorouracil and cisplatin, and radiation has improved outcome for patients with esophageal cancer. A randomized controlled…”
Get full text

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials by Argiris, A., Li, S., Ghebremichael, M., Egloff, A.M., Wang, L., Forastiere, A.A., Burtness, B., Mehra, R.

“…The purpose of this article was to study the association of human papillomavirus (HPV) with clinical outcomes in patients with recurrent or metastatic squamous…”
Get full text

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer by KURZROCK, Razelle, SHERMAN, Steven I, HONG, David S, NG, Chaan S, LEI YE, GAGEL, Robert F, FRYE, John, MÜLLER, Thomas, RATAIN, Mark J, SALGIA, Ravi, BALL, Douglas W, FORASTIERE, Arlene A, COHEN, Roger B, MEHRA, Ranee, PFISTER, David G, COHEN, Ezra E. W, JANISCH, Linda, NAULING, Forlisa

“…XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and…”
Get full text

Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? by Quon, Harry, Forastiere, Arlene A

Get full text

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial by Vermorken, Jan B, Dr, Stöhlmacher-Williams, Jan, MD, Davidenko, Irina, MD, Licitra, Lisa, MD, Winquist, Eric, MD, Villanueva, Cristian, MD, Foa, Paolo, MD, Rottey, Sylvie, MD, Skladowski, Krzysztof, MD, Tahara, Makoto, MD, Pai, Vasant R, MD, Faivre, Sandrine, MD, Blajman, Cesar R, MD, Forastiere, Arlene A, MD, Stein, Brian N, MBBS, Oliner, Kelly S, PhD, Pan, Zhiying, PhD, Bach, Bruce A, MD

“…Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic…”
Get full text

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 by Al-Sarraf, M, LeBlanc, M, Giri, P G, Fu, K K, Cooper, J, Vuong, T, Forastiere, A A, Adams, G, Sakr, W A, Schuller, D E, Ensley, J F

“…The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative…”
Get full text

Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer by Forastiere, Arlene A, Goepfert, Helmuth, Maor, Moshe, Pajak, Thomas F, Weber, Randal, Morrison, William, Glisson, Bonnie, Trotti, Andy, Ridge, John A, Chao, Clifford, Peters, Glen, Lee, Ding-Jen, Leaf, Andrea, Ensley, John, Cooper, Jay

“…This randomized trial of treatment for advanced laryngeal cancer found that concurrent chemotherapy and radiotherapy was superior to chemotherapy followed by…”
Get full text

Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group by GIBSON, Michael K, YI LI, MURPHY, Barbara, HUSSAIN, Maha H. A, DECONTI, Ronald C, ENSLEY, John, FORASTIERE, Arlene A

“…To determine the response rate, survival and toxicity of infusional cisplatin plus fluorouracil (CF) versus cisplatin plus paclitaxel (CP) in patients with…”
Get full text

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study by COHEN, Ezra E. W, ROSEN, Lee S, TORTORICI, Michael, SHALINSKY, David R, LIAU, Katherine F, COHEN, Roger B, VOKES, Everett E, KIES, Merrill S, FORASTIERE, Arlene A, WARDEN, Francis P, KANE, Madeleine A, SHERMAN, Eric, KIM, Sinil, BYCOTT, Paul

“…Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This…”
Get full text

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck by Cooper, Jay S, Pajak, Thomas F, Forastiere, Arlene A, Jacobs, John, Campbell, Bruce H, Saxman, Scott B, Kish, Julie A, Kim, Harold E, Cmelak, Anthony J, Rotman, Marvin, Machtay, Mitchell, Ensley, John F, Chao, K.S. Clifford, Schultz, Christopher J, Lee, Nancy, Fu, Karen K

“…In this randomized trial of the postoperative treatment of high-risk squamous-cell carcinoma of the head and neck, concurrent radiotherapy plus chemotherapy…”
Get full text

An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer by ADELSTEIN, David J, YI LI, ADAMS, George L, WAGNER, Henry JR, KISH, Julie A, ENSLEY, John F, SCHULLER, David E, FORASTIERE, Arlene A

“…The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable…”
Get full text